S&P 500   4,485.90 (+0.32%)
DOW   35,251.47 (-0.12%)
QQQ   372.36 (+0.93%)
AAPL   146.64 (+1.24%)
MSFT   306.64 (+0.80%)
FB   335.44 (+3.29%)
GOOGL   2,850.27 (+0.81%)
TSLA   869.98 (+3.20%)
AMZN   3,446.78 (+1.11%)
NVDA   222.03 (+1.56%)
BABA   167.20 (-0.48%)
NIO   39.51 (+4.77%)
CGC   13.21 (-1.05%)
GE   104.22 (-0.18%)
MU   67.14 (-0.80%)
AMD   116.42 (+3.84%)
T   25.36 (-1.32%)
F   15.59 (-0.70%)
ACB   6.93 (-1.42%)
DIS   170.64 (-3.30%)
PFE   41.34 (-0.36%)
BA   216.74 (-0.14%)
AMC   42.83 (+5.13%)
S&P 500   4,485.90 (+0.32%)
DOW   35,251.47 (-0.12%)
QQQ   372.36 (+0.93%)
AAPL   146.64 (+1.24%)
MSFT   306.64 (+0.80%)
FB   335.44 (+3.29%)
GOOGL   2,850.27 (+0.81%)
TSLA   869.98 (+3.20%)
AMZN   3,446.78 (+1.11%)
NVDA   222.03 (+1.56%)
BABA   167.20 (-0.48%)
NIO   39.51 (+4.77%)
CGC   13.21 (-1.05%)
GE   104.22 (-0.18%)
MU   67.14 (-0.80%)
AMD   116.42 (+3.84%)
T   25.36 (-1.32%)
F   15.59 (-0.70%)
ACB   6.93 (-1.42%)
DIS   170.64 (-3.30%)
PFE   41.34 (-0.36%)
BA   216.74 (-0.14%)
AMC   42.83 (+5.13%)
S&P 500   4,485.90 (+0.32%)
DOW   35,251.47 (-0.12%)
QQQ   372.36 (+0.93%)
AAPL   146.64 (+1.24%)
MSFT   306.64 (+0.80%)
FB   335.44 (+3.29%)
GOOGL   2,850.27 (+0.81%)
TSLA   869.98 (+3.20%)
AMZN   3,446.78 (+1.11%)
NVDA   222.03 (+1.56%)
BABA   167.20 (-0.48%)
NIO   39.51 (+4.77%)
CGC   13.21 (-1.05%)
GE   104.22 (-0.18%)
MU   67.14 (-0.80%)
AMD   116.42 (+3.84%)
T   25.36 (-1.32%)
F   15.59 (-0.70%)
ACB   6.93 (-1.42%)
DIS   170.64 (-3.30%)
PFE   41.34 (-0.36%)
BA   216.74 (-0.14%)
AMC   42.83 (+5.13%)
S&P 500   4,485.90 (+0.32%)
DOW   35,251.47 (-0.12%)
QQQ   372.36 (+0.93%)
AAPL   146.64 (+1.24%)
MSFT   306.64 (+0.80%)
FB   335.44 (+3.29%)
GOOGL   2,850.27 (+0.81%)
TSLA   869.98 (+3.20%)
AMZN   3,446.78 (+1.11%)
NVDA   222.03 (+1.56%)
BABA   167.20 (-0.48%)
NIO   39.51 (+4.77%)
CGC   13.21 (-1.05%)
GE   104.22 (-0.18%)
MU   67.14 (-0.80%)
AMD   116.42 (+3.84%)
T   25.36 (-1.32%)
F   15.59 (-0.70%)
ACB   6.93 (-1.42%)
DIS   170.64 (-3.30%)
PFE   41.34 (-0.36%)
BA   216.74 (-0.14%)
AMC   42.83 (+5.13%)

Compare Stocks

Date Range: 

 CRISPR TherapeuticsNeurocrine BiosciencesAcceleron PharmaVir BiotechnologyFate Therapeutics
SymbolNASDAQ:CRSPNASDAQ:NBIXNASDAQ:XLRNNASDAQ:VIRNASDAQ:FATE
Price Information
Current Price$96.17$104.12$173.17$38.79$60.13
50-Day Moving Average$117.26$95.67$145.04$45.00$70.23
52-Week Low$84.38$84.77$99.98$25.31$42.64
52-Week High$220.20$120.27$189.99$141.01$121.16
MarketRank™
Overall Score2.22.52.02.12.3
Analysis Score3.32.32.13.13.4
Community Score4.75.04.93.34.9
Dividend Score0.00.00.00.00.0
Ownership Score2.52.52.53.33.3
Earnings & Valuation Score0.62.50.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyHoldHoldBuy
Consensus Price Target$161.13$119.46$171.29$67.00$111.00
% Upside from Price Target67.55% upside14.73% upside-1.09% downside72.72% upside84.60% upside
Trade Information
Market Cap$7.33 billion$9.84 billion$10.55 billion$5.07 billion$5.72 billion
Beta2.260.730.35-1.681.74
Average Volume1,641,844862,089502,2731,188,1931,020,020
Sales & Book Value
Annual Revenue$720,000.00$1.05 billion$92.52 million$76.37 million$31.43 million
Price / Sales10,178.139.41113.9966.34182.10
CashflowN/A$5.01 per shareN/AN/AN/A
Price / CashN/A20.78N/AN/AN/A
Book Value$23.37 per share$11.99 per share$14.19 per share$5.63 per share$4.41 per share
Price / Book4.128.6812.206.8913.63
Profitability
Net Income$-348.86 million$407.30 million$-166.03 million$-298.67 million$-173.39 million
EPS($5.29)$4.16($2.92)($2.51)($1.52)
Trailing P/E Ratio18.8227.99N/AN/AN/A
Forward P/E RatioN/A28.60N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins49.52%35.34%-221.15%-162.75%-441.63%
Return on Equity (ROE)24.08%33.04%-26.79%-40.77%-27.96%
Return on Assets (ROA)21.86%20.72%-24.79%-29.33%-19.85%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.26%N/AN/AN/A
Current Ratio26.23%5.21%12.07%5.91%6.75%
Quick Ratio26.23%5.08%12.07%5.91%6.75%
Ownership Information
Institutional Ownership Percentage52.68%95.99%87.94%58.62%98.36%
Insider Ownership Percentage10.70%4.30%1.70%37.20%18.58%
Miscellaneous
Employees410845312327279
Shares Outstanding76.20 million94.55 million60.90 million130.61 million95.19 million
Next Earnings Date10/27/2021 (Estimated)11/1/2021 (Confirmed)11/4/2021 (Estimated)11/9/2021 (Estimated)11/4/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Is Fate Therapeutics Inc. (NASDAQ: FATE) A Good Investment Now?Is Fate Therapeutics Inc. (NASDAQ: FATE) A Good Investment Now?
stocksregister.com - October 16 at 1:00 PM
San Diego biotech veterans launch novel therapeutics firm targeting cancer, other diseasesSan Diego biotech veterans launch novel therapeutics firm targeting cancer, other diseases
sandiegouniontribune.com - October 16 at 1:46 AM
San Diego’s Top Public Companies See Big Market Cap Gains in FY ’21San Diego’s Top Public Companies See Big Market Cap Gains in FY ’21
sdbj.com - October 11 at 4:07 AM
The Business Case For Buying Fate Therapeutics Inc. (NASDAQ: FATE) Stock NowThe Business Case For Buying Fate Therapeutics Inc. (NASDAQ: FATE) Stock Now
stocksregister.com - October 5 at 10:05 AM
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 ...Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 ...
apnews.com - October 2 at 3:43 AM
Fate Therapeutics Inc. (FATE) Is Worth Investing InFate Therapeutics Inc. (FATE) Is Worth Investing In
stocksregister.com - October 1 at 12:41 PM
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual MeetingFate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
finance.yahoo.com - October 1 at 12:41 PM
Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment PlansStem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans
prnewswire.com - October 1 at 7:40 AM
Fate Therapeutics Enters Oversold Territory (FATE)Fate Therapeutics Enters Oversold Territory (FATE)
nasdaq.com - September 30 at 9:39 PM
How Will Fate Therapeutics Inc. (NASDAQ: FATE) Perform In The Next Few Months?How Will Fate Therapeutics Inc. (NASDAQ: FATE) Perform In The Next Few Months?
marketingsentinel.com - September 29 at 6:46 PM
Fate Therapeutics (NASDAQ:FATE) Trading Down 4.9%Fate Therapeutics (NASDAQ:FATE) Trading Down 4.9%
americanbankingnews.com - September 24 at 12:18 PM
Were Not Very Worried About Fate Therapeutics (NASDAQ:FATE) Cash Burn RateWe're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
nasdaq.com - September 23 at 1:03 PM
Premarket Movers: BlackBerry, Joby Aviation, Liberty Global Cl BPremarket Movers: BlackBerry, Joby Aviation, Liberty Global Cl B
barrons.com - September 23 at 8:02 AM
Should This Make Fate Therapeutics Inc. (NASDAQ: FATE) Investors Worry?Should This Make Fate Therapeutics Inc. (NASDAQ: FATE) Investors Worry?
stocksregister.com - September 21 at 8:33 AM
First Week of May 2022 Options Trading For Fate TherapeuticsFirst Week of May 2022 Options Trading For Fate Therapeutics
nasdaq.com - September 20 at 3:09 PM
Press Release: Fate Therapeutics Announces -2-Press Release: Fate Therapeutics Announces -2-
sharecast.com - September 15 at 9:56 AM
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine SupportFate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
finance.yahoo.com - September 15 at 9:56 AM
Recent Poor Results Have Made This Promising Cathie Wood Pick a BargainRecent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
finance.yahoo.com - September 14 at 6:38 PM
Fate Therapeutics Inc. (FATE) Stock Behavior Isn’t As Predictable As You ThinkFate Therapeutics Inc. (FATE) Stock Behavior Isn’t As Predictable As You Think
stocksregister.com - September 11 at 5:09 PM
Zillow – 2 Stocks in Cathie Wood’s ARK innovation Fund Wall Street Predicts Will Rally by 40% By StockNewsZillow – 2 Stocks in Cathie Wood’s ARK innovation Fund Wall Street Predicts Will Rally by 40% By StockNews
fintechzoom.com - September 9 at 10:24 PM
2 Stocks in Cathie Wood’s ARK innovation Fund Wall Street Predicts Will Rally by 40%2 Stocks in Cathie Wood’s ARK innovation Fund Wall Street Predicts Will Rally by 40%
stocknews.com - September 9 at 5:24 PM
Fate Therapeutics Inc. (NASDAQ:FATE) Forecast To Rise 33.29% To Reach Consensus Target PriceFate Therapeutics Inc. (NASDAQ:FATE) Forecast To Rise 33.29% To Reach Consensus Target Price
marketingsentinel.com - September 8 at 5:38 PM
What Will Fate Therapeutics Inc. (NASDAQ: FATE) Be Like In 2021What Will Fate Therapeutics Inc. (NASDAQ: FATE) Be Like In 2021
stocksregister.com - September 4 at 4:20 PM
Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?
finance.yahoo.com - September 3 at 5:55 PM
Synthetic Biology Engineers the Next Genomic RevolutionSynthetic Biology Engineers the Next Genomic Revolution
genengnews.com - September 1 at 5:24 PM
DateCompanyBrokerageAction
10/14/2021Neurocrine BiosciencesMorgan Stanley
Downgrade
10/13/2021CRISPR TherapeuticsChardan Capital
Reiterated Rating
10/13/2021CRISPR TherapeuticsStifel Nicolaus
Lower Price Target
10/13/2021CRISPR TherapeuticsWilliam Blair
Reiterated Rating
10/6/2021Acceleron PharmaJefferies Financial Group
Initiated Coverage
10/4/2021Acceleron PharmaRaymond James
Downgrade
10/1/2021Acceleron PharmaMorgan Stanley
Reiterated Rating
10/1/2021Acceleron PharmaBarclays
Downgrade
9/30/2021Neurocrine BiosciencesHC Wainwright
Reiterated Rating
9/30/2021Acceleron PharmaCowen
Downgrade
9/30/2021Acceleron PharmaMorgan Stanley
Downgrade
9/30/2021Acceleron PharmaHC Wainwright
Downgrade
9/30/2021Acceleron PharmaPiper Sandler
Downgrade
9/30/2021Acceleron PharmaSVB Leerink
Boost Price Target
9/27/2021Acceleron PharmaRoyal Bank of Canada
Boost Price Target
9/22/2021Neurocrine BiosciencesNeedham & Company LLC
Initiated Coverage
9/22/2021Vir BiotechnologyThe Goldman Sachs Group
Downgrade
8/26/2021Fate TherapeuticsMorgan Stanley
Initiated Coverage
8/23/2021Fate TherapeuticsHC Wainwright
Reiterated Rating
8/16/2021CRISPR TherapeuticsCanaccord Genuity
Boost Price Target
8/6/2021Neurocrine BiosciencesCanaccord Genuity
Downgrade
8/6/2021Vir BiotechnologyBarclays
Lower Price Target
8/5/2021Acceleron PharmaPiper Sandler
Boost Price Target
8/5/2021Fate TherapeuticsHC Wainwright
Boost Price Target
8/5/2021Fate TherapeuticsSVB Leerink
Lower Price Target
8/4/2021Neurocrine BiosciencesMorgan Stanley
Lower Price Target
7/30/2021CRISPR TherapeuticsChardan Capital
Lower Price Target
7/19/2021Acceleron PharmaWolfe Research
Initiated Coverage
7/16/2021Neurocrine BiosciencesHC Wainwright
Reiterated Rating
7/9/2021Fate TherapeuticsStifel Nicolaus
Reiterated Rating
7/7/2021CRISPR TherapeuticsChardan Capital
Reiterated Rating
6/28/2021Vir BiotechnologyNeedham & Company LLC
Reiterated Rating
6/27/2021Acceleron PharmaSVB Leerink
Reiterated Rating
6/24/2021Acceleron PharmaOppenheimer
Boost Price Target
6/15/2021Acceleron PharmaSVB Leerink
Reiterated Rating
6/14/2021CRISPR TherapeuticsCitigroup
Upgrade
6/7/2021Fate TherapeuticsHC Wainwright
Upgrade
5/18/2021Neurocrine BiosciencesThe Goldman Sachs Group
Initiated Coverage
5/14/2021Fate TherapeuticsWedbush
Downgrade
5/13/2021CRISPR TherapeuticsEvercore ISI
Upgrade
5/7/2021Fate TherapeuticsWedbush
Upgrade
5/6/2021Neurocrine BiosciencesWedbush
Lower Price Target
5/6/2021Neurocrine BiosciencesOppenheimer
Lower Price Target
5/6/2021Neurocrine BiosciencesMorgan Stanley
Lower Price Target
5/6/2021Neurocrine BiosciencesSVB Leerink
Lower Price Target
5/6/2021Neurocrine BiosciencesBarclays
Upgrade
5/3/2021Neurocrine BiosciencesMizuho
Lower Price Target
4/26/2021Neurocrine BiosciencesMizuho
Lower Price Target
4/26/2021Fate TherapeuticsJefferies Financial Group
Initiated Coverage
4/21/2021CRISPR TherapeuticsBarclays
Boost Price Target
4/21/2021CRISPR TherapeuticsJefferies Financial Group
Upgrade
4/19/2021Neurocrine BiosciencesMorgan Stanley
Boost Price Target
4/16/2021Vir BiotechnologyNeedham & Company LLC
Reiterated Rating
4/12/2021Neurocrine BiosciencesWedbush
Lower Price Target
3/29/2021Acceleron PharmaThe Goldman Sachs Group
Reiterated Rating
3/29/2021Acceleron PharmaSVB Leerink
Reiterated Rating
3/23/2021Acceleron PharmaSVB Leerink
Downgrade
3/22/2021Acceleron PharmaThe Goldman Sachs Group
Reiterated Rating
3/12/2021Fate TherapeuticsSVB Leerink
Boost Price Target
3/11/2021Acceleron PharmaWolfe Research
Initiated Coverage
3/8/2021Vir BiotechnologyHC Wainwright
Boost Price Target
3/8/2021Vir BiotechnologyNeedham & Company LLC
Boost Price Target
3/5/2021Neurocrine BiosciencesRobert W. Baird
Reiterated Rating
3/4/2021CRISPR TherapeuticsJMP Securities
Initiated Coverage
3/4/2021Fate TherapeuticsWedbush
Reiterated Rating
3/4/2021Fate TherapeuticsWells Fargo & Company
Boost Price Target
3/3/2021Vir BiotechnologyThe Goldman Sachs Group
Boost Price Target
3/2/2021Vir BiotechnologyNeedham & Company LLC
Boost Price Target
3/1/2021CRISPR TherapeuticsBarclays
Boost Price Target
3/1/2021Acceleron PharmaCitigroup
Boost Price Target
2/28/2021CRISPR TherapeuticsBarclays
Reiterated Rating
2/26/2021Acceleron PharmaPiper Sandler
Boost Price Target
2/26/2021Acceleron PharmaMorgan Stanley
Boost Price Target
2/26/2021Acceleron PharmaSVB Leerink
Boost Price Target
2/26/2021Fate TherapeuticsTruist
Boost Price Target
2/26/2021Fate TherapeuticsBank of America
Initiated Coverage
2/26/2021Fate TherapeuticsWedbush
Downgrade
2/25/2021Vir BiotechnologyBarclays
Boost Price Target
2/25/2021Fate TherapeuticsRoth Capital
Boost Price Target
2/25/2021Fate TherapeuticsCantor Fitzgerald
Boost Price Target
2/25/2021Fate TherapeuticsMizuho
Boost Price Target
2/17/2021CRISPR TherapeuticsThe Goldman Sachs Group
Lower Price Target
2/17/2021CRISPR TherapeuticsOppenheimer
Boost Price Target
2/17/2021CRISPR TherapeuticsChardan Capital
Boost Price Target
2/17/2021CRISPR TherapeuticsNeedham & Company LLC
Reiterated Rating
2/17/2021Fate TherapeuticsPiper Sandler
Boost Price Target
2/11/2021Fate TherapeuticsCitigroup
Downgrade
2/5/2021Neurocrine BiosciencesMizuho
Boost Price Target
2/1/2021Neurocrine BiosciencesRaymond James
Initiated Coverage
1/29/2021Acceleron PharmaJPMorgan Chase & Co.
Boost Price Target
1/27/2021Vir BiotechnologyJPMorgan Chase & Co.
Downgrade
1/27/2021Fate TherapeuticsHC Wainwright
Reiterated Rating
1/26/2021Neurocrine BiosciencesWilliam Blair
Reiterated Rating
1/25/2021Fate TherapeuticsBMO Capital Markets
Boost Price Target
1/21/2021Neurocrine BiosciencesCanaccord Genuity
Reiterated Rating
1/20/2021Vir BiotechnologyHC Wainwright
Boost Price Target
1/19/2021Fate TherapeuticsOppenheimer
Reiterated Rating
1/15/2021Fate TherapeuticsBarclays
Boost Price Target
1/12/2021CRISPR TherapeuticsTruist
Boost Price Target
12/29/2020Neurocrine BiosciencesCantor Fitzgerald
Lower Price Target
12/25/2020Vir BiotechnologyRobert W. Baird
Reiterated Rating
12/24/2020Vir BiotechnologyRobert W. Baird
Reiterated Rating
12/21/2020Fate TherapeuticsStifel Nicolaus
Boost Price Target
12/16/2020Neurocrine BiosciencesMorgan Stanley
Lower Price Target
12/10/2020CRISPR TherapeuticsChardan Capital
Boost Price Target
12/10/2020CRISPR TherapeuticsJefferies Financial Group
Downgrade
12/10/2020CRISPR TherapeuticsNeedham & Company LLC
Boost Price Target
12/10/2020CRISPR TherapeuticsPiper Sandler
Boost Price Target
12/7/2020CRISPR TherapeuticsStifel Nicolaus
Boost Price Target
12/7/2020CRISPR TherapeuticsCanaccord Genuity
Boost Price Target
12/7/2020CRISPR TherapeuticsOppenheimer
Boost Price Target
12/7/2020Neurocrine BiosciencesWedbush
Lower Price Target
11/12/2020Neurocrine BiosciencesCanaccord Genuity
Lower Price Target
10/7/2020Vir BiotechnologyHC Wainwright
Boost Price Target
10/5/2020Vir BiotechnologyBank of America
Initiated Coverage
9/21/2020Vir BiotechnologyHC Wainwright
Boost Price Target
9/14/2020Vir BiotechnologyThe Goldman Sachs Group
Upgrade
9/11/2020Vir BiotechnologyJPMorgan Chase & Co.
Upgrade
8/31/2020Vir BiotechnologyThe Goldman Sachs Group
Boost Price Target
8/24/2020Vir BiotechnologyHC Wainwright
Reiterated Rating
8/20/2020Vir BiotechnologyNeedham & Company LLC
Initiated Coverage
8/12/2020Vir BiotechnologyBarclays
Boost Price Target
5/13/2020Vir BiotechnologyBarclays
Boost Price Target
3/29/2020Vir BiotechnologyBarclays
Reiterated Rating
3/27/2020Vir BiotechnologyRobert W. Baird
Boost Price Target
(Data available from 10/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.